TOKYO, June 6, 2016 /PRNewswire/ -- Daiichi Sankyo Co., Ltd. (JP: 4568.T, OTC Pink: DSNKY) based in Tokyo, Japan and focused on pharmaceutical business, today announced that Senior Director, IR group, Mr. Junichi Onuma will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on June 9th. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to US investors.
DATE: June 9th, 2016
TIME: 9.00am ET
LINK: www.adr.db.com/dbvic
This will be a live online event where investors in the US are invited to ask international companies their questions and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group's research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com.
